SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK908.29m
- SEK894.99m
Brief: Synact Pharma To Carry Out Directed Issues, Fully Guaranteed Rights Issue
Brief: SynAct Pharma Q3 Sales SEK 0
Brief: Synact Pharma Says Current Cash, Cash Equivalents Insufficient To Meet Co's Liquidity Needs Over Next 12 Months
Brief: SynAct Pharma Q2 Sales SEK 0
Brief: Anders Kronborg Is Elected As Chairman Of SynAct Pharma
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Completes Directed Issues Of 49.2 MSEK
Brief: GoodWind Distributed 977,256 Synact Pharma Shares As Dividend
Brief: Synact Pharma Appoints Jeppe Øvlesen As CEO
Brief: SynAct Pharma Updates On Resolve P2a Clinical Trial
Brief: SynAct Pharma Q4 Sales SEK 0
Brief: Synact Pharma Q4 Operating Expenses Up At SEK 91.1 Mln
Brief: Synact Pharma Announces Additional Data From Expand P2B Clinical Trial
Brief: SynAct Pharma Q3 Adjusted EPS SEK -1
Brief: Synact Pharma Announces Additional Data From Expand P2b Clinical Trial
Brief: SynAct Pharma Identifies Sub-Population Of Patients Responding To Resomelagon
Brief: Synact Pharma Announces Top Line Data From Expand P2b Clinical Trial
Brief: SynAct Pharma Completes Dosing In Part A Of Combined Phase 2a/b Resolve Study Of Resomelagon (AP1189) In Rheumatoid Arthritis (RA)
Brief: SynAct Pharma Q2 Net Income at SEK -43.511 Million